

Company Overview

We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid drug conjugate™ (PDCs™) delivery platform to develop PDCs that specifically target cancer cells to deliver improved efficacy and better safety as a result of fewer off-target effects. The PDC™ platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments and we plan to develop PDCs independently and through research and development collaborations.

FDA Grants Exemption to Import Alert for Cellecstar's CLR 131 in Pediatric and Adolescent Patients

Mar 19 2019, 8:30 AM EDT

Cellecstar Reports Financial Results for Year Ended December 31, 2018 and Provides a Corporate Update

Feb 26 2019, 8:30 AM EST

Cellecstar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131

Feb 25 2019, 8:30 AM EST

Stock Overview

| | | |
|------------|------------------|-----------------------------|
| Symbol | CLRB | LifeSci Advisors |
| Exchange | Nasdaq | Monique Kosse |
| Market Cap | 11.13m | Managing Director |
| Last Price | \$2.34 | T: 646-915-3820 |
| 52-Week | \$1.22 - \$12.76 | monique@lifesciadvisors.com |

04/18/2019 04:00 PM EDT

Investor Relations

Management Team

James Caruso

President, CEO and Director

Jarrold Longcor

Chief Business Officer

Charles "Chip" Bernhardt

Interim Chief Financial Officer

Cellecstar Biosciences, Inc.

100 Campus Drive, Suite 207
Florham Park, NJ 07932

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.